

## STRIVING TOWARDS THE ELIMINATION OF HCV INFECTION

02-03 FEBRUARY 2018

BERLIN, GERMANY

### SCIENTIFIC ORGANISING COMMITTEE

Alessio Aghemo, *Italy*

Jason Grebely, *Australia*

Francesco Negro, *Switzerland*

### PRELIMINARY\* PROGRAMME

#### DAY 1 – Friday, 2 February 2018

08:00–08:10                      Welcome and introductory remarks  
Francesco Negro, *Switzerland*

#### 1. EPIDEMIOLOGY AND PREVENTION

Chairs:                              Jason Grebely, *Australia*  
Dagmar Hedrich, *Portugal*

08:10–08:20                      Patient experience  
Andi Hüttenmoser, *Switzerland*

08:20–08:40                      Global HCV epidemiology  
Angelos Hatzakis, *Greece*

08:40–09:00                      Morbidity and mortality associated with HCV infection  
Sharon Hutchinson, *United Kingdom*

09:00–09:20                      Successful interventions for the prevention of HCV infection  
Matthew Hickman, *United Kingdom*

09:20–09:40                      Do we still need a vaccine for HCV?  
Andrea Cox, *United States*

09:40–10:10                      Discussion

10:10 – 10:30                      Coffee break and ePoster session 1

\*Subject to change

## 2. INTERVENTIONS TO IMPROVE LINKAGE OF PATIENTS TO HCV TESTING, CARE, AND TREATMENT

Chairs:	Martin Kaberg, <i>Sweden</i> John Dillon, <i>United Kingdom</i>
10:30–10:50	Successful strategies to enhance HCV testing, linkage to care, and treatment Jason Grebely, <i>Australia</i>
10:50–11:10	Diagnostic tools to improve HCV testing and diagnosis: where do we stand? Jean-Michel Pawlotsky, <i>France</i>
11:10–11:30	Scale-up of interventions to improve testing, care and treatment: lessons learned from HIV Philippa Easterbrook, <i>Switzerland</i>
11:30–11:50	Engaging marginalized patients in the DAA era Magdalena Harris, <i>United Kingdom</i>
11:50–12:20	Discussion
12:20–13:30	Lunch break and ePoster sessions 2 and 3

## 3. TREATMENT OF HCV

Chairs:	Alessio Aghemo, <i>Italy</i> Marieta Simonova, <i>Bulgaria</i>
13:30–13:50	Management of acute HCV infection Heiner Wedemeyer, <i>Germany</i>
13:50–14:10	Management of chronic HCV infection Stefan Zeuzem, <i>Germany</i>
14:10–14:30	Direct-acting interferon-free therapies among people who inject drugs Olav Dalgard, <i>Norway</i>
14:30–14:50	Managing direct-acting antiviral therapy among people with HIV/HCV co-infection Jürgen Rockstroh, <i>Germany</i>
14:50–15:10	Management of treatment failures Massimo Puoti, <i>Italy</i>
15:10–15:30	Discussion
15:30 – 16:00	Coffee break and ePoster session 4

\*Subject to change

#### 4. SETTINGS TO FACILITATE HCV ELIMINATION

Chairs:	Angelos Hatzakis, <i>Greece</i> Sharon Hutchinson, <i>United Kingdom</i>
16:00–16:20	Prisons Gregory Dore, <i>Australia</i>
16:20–16:40	Drug, alcohol and psychiatry clinics Martin Kaberg, <i>Sweden</i>
16:40–17:00	General practices, community health centres, and pharmacies John Dillon, <i>United Kingdom</i>
17:00–17:20	Clinical reality treatment landscape in Eastern Europe Marieta Simonova, <i>Bulgaria</i>
17:20–17:40	Clinical reality treatment landscape in Western Europe Christophe Hézode, <i>France</i>
17:40–18:00	Discussion

### DAY 2 – Saturday 3 February 2018

#### 5. HOW FAR ARE WE FROM REACHING THE WHO TARGETS OF HCV ELIMINATION?

Chairs:	Andrea Cox, <i>United States</i> Graham Foster, <i>United Kingdom</i>
08:00–08:20	WHO elimination targets and the development of national viral hepatitis plans Philippa Easterbrook, <i>Switzerland</i>
08:20–08:40	What is required from a health systems perspective to achieve HCV elimination? Jeffrey Lazarus, <i>Denmark</i>
08:40–09:00	Cost-effectiveness vs. affordability of HCV treatments John Cairns, <i>United Kingdom</i>
09:00–09:20	MPP model to scale up access to generic medicines with special focus on LMICs Ludmila Maistat, <i>Switzerland</i>
09:20–09:40	<b>The role of patients' associations</b> Tatjana Reic, <i>United Kingdom</i>
09:40–10:30	Coffee break and ePoster sessions 5 and 6

\*Subject to change

10:30–10:45	The Australian experience Gregory Dore, <i>Australia</i>
10:45–11:00	The UK experience Graham Foster, <i>United Kingdom</i>
11:00–11:20	The role of payers Ricardo Baptiste Leite, <i>Portugal</i>
11:20–11:50	The contribution from the industry Fernando Tatsch, <i>United States</i> (10 min) Gregg H. Alton, <i>United States</i> (10 min) Michael Robertson, <i>United States</i> (10 min)
11:50–12:30	Panel discussion (all speakers from session 5 on stage)
12:30–14:00	Lunch break and ePoster session 7 and 8
14:00–14:30	State-of-the-Art lecture Rise and fall of a virus Antonio Craxi, <i>Italy</i>

## 6. IS THE GAME OVER? THE CHALLENGE OF POST-SVR MANAGEMENT

Chairs:	Massimo Puoti, <i>Italy</i> Stefan Zeuzem, <i>Germany</i>
14:30–14:50	HCV reinfection following successful DAA therapy Patrick Ingiliz, <i>Germany</i>
14:50–15:10	Harm reduction and drug user health Dagmar Hedrich, <i>Portugal</i>
15:10–15:30	Beyond the liver: SVR and extrahepatic manifestations Francesco Negro, <i>Switzerland</i>
15:30–15:50	Alcohol and SVR: yes, how much, not at all Nick Sheron, <i>United Kingdom</i>
15:50–16:10	The post-SVR HCC risk: life-long follow-up? Alessio Aghemo, <i>Italy</i>
16:10–16:30	Discussion
16:30–16:40	Concluding remarks

\*Subject to change